Intranasal Ketamine | 703-844-0184 | Fairfax, Va 22304 | Ketamine Treatment Center | Dr. Sendi | Ketamine for depression | Depression Treatment Center | CBD Doctor | Nasal Ketamine Provider | McLean, Va | Arlington, Va 22230 | 703-844-0184 | Loudoun, Va Ketamine Treatment


Intranasal Ketamine for Treatment-Resistant Depression

Call 703-844-0184 For a Ketamine Treatment Evaluation | Fairfax, Va 22304

NOVA Health Recovery Ketamine Treatment Center

Intranasal Ketamine Provider | 703-844-0184

There is an urgent need for better medications that work quickly for treatment of major depression and bipolar disorder. The treatment should also be tolerable and work for depressed patients who have not responded to conventional treatments, ie, who have treatment-resistant depression (TRD).

NOVA Health Recovery Ketamine Treatment Center | 703-844-0184 | Alexandria, Va 22306

References: Depress Anxiety. 2016 Aug;33(8):698-710.  Gen Hosp Psychiatry. 2015;37(2):178–184.  J Clin Psychiatry. 2015 May;76(5):e628-31.  Biol Psychiatry. 2014 Dec 15;76(12):970-6.  American Psychiatric Association (APA) 2018. Abstracts P7-065 and P8-054, presented May 8, 2018. Psychiatry Clin Neurosci. 2018 May 10.  J Clin Psychiatry. 2017 Jun;78(6):e674-e677.  CNS Drugs. 2018 May 7. [Epub ahead of print] J Psychopharmacol. 2018 Apr;32(4):397-407.

Ketamine 25mg – 100 mg Nasal Spray

BACKGROUND: The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered via an intravenous route, has shown rapid antidepressant effects in patients with treatment-resistant depression. The current study was designed to test the safety, tolerability, and efficacy of intranasal ketamine in patients with depression who had failed at least one prior antidepressant trial. METHODS: In a randomized, double-blind, crossover study, 20 patients with major depression were randomly assigned, and 18 completed 2 treatment days with intranasal ketamine hydrochloride (50 mg) or saline solution. The primary efficacy outcome measure was change in depression severity 24 hours after ketamine or placebo, measured using the Montgomery-Åsberg Depression Rating Scale. Secondary outcomes included persistence of benefit, changes in self-reports of depression, changes in anxiety, and proportion of responders. Potential psychotomimetic, dissociative, hemodynamic, and general adverse effects associated with ketamine were also measured. RESULTS: Patients showed significant improvement in depressive symptoms at 24 hours after ketamine compared to placebo (t = 4.39, p < .001; estimated mean Montgomery-Åsberg Depression Rating Scale score difference of 7.6 ± 3.7; 95% confidence interval, 3.9-11.3). Response criteria were met by 8 of 18 patients (44%) 24 hours after ketamine administration compared with 1 of 18 (6%) after placebo (p = .033). Intranasal ketamine was well tolerated with minimal psychotomimetic or dissociative effects and was not associated with clinically significant changes in hemodynamic parameters. CONCLUSIONS: This study provides the first controlled evidence for the rapid antidepressant effects of intranasal ketamine. Treatment was associated with minimal adverse effects. If replicated, these findings may lead to novel approaches to the pharmacologic treatment of patients with major depression   Link Link to Intranasal Ketamine

Submit a Comment

Your email address will not be published. Required fields are marked *